Wade Amanda, Draper Bridget, Doyle Joseph, Allard Nicole, Grinzi Paul, Thompson Alexander, Hellard Margaret
Aust Fam Physician. 2017;46(4):235-240.
To increase access to hepatitis C virus (HCV) treatment, the Pharmaceutical Benefits Scheme (PBS) enabled general practitioners (GPs) to prescribe direct-acting antiviral (DAA) therapy. We conducted a survey to identify GPs' knowledge and management of HCV.
A questionnaire consisting of 20 items about HCV knowledge and management was sent to 1000 GPs.
One hundred and ninety-one GPs (19.1%) responded; 74% answered correctly that antibody and RNA positivity is diagnostic of HCV. Only 12% could directly request transient elastography. Although 53% of respondents reported interest in prescribing DAAs, 72% continued to refer all patients to specialists. Fifty-five per cent were unsure if people who currently inject drugs were eligible for treatment.
Most respondents were interested in prescribing DAAs, but education, access to transient elastography and clear consultation pathways are required to translate this interest into increased treatment availability. PBS eligibility of current injectors needs promotion.
为了增加丙型肝炎病毒（HCV）治疗的可及性，药品福利计划（PBS）允许全科医生（GPs）开具直接抗病毒药物（DAA）疗法。我们开展了一项调查，以确定全科医生对HCV的了解和管理情况。
向1000名全科医生发送了一份包含20项关于HCV知识和管理内容的问卷。
191名全科医生（19.1%）做出了回应；74%正确回答抗体和RNA阳性可诊断HCV。只有12%能够直接要求进行瞬时弹性成像检查。尽管53%的受访者表示有兴趣开具DAA药物，但72%的人仍继续将所有患者转诊给专科医生。55%的人不确定目前注射毒品的人是否有资格接受治疗。
大多数受访者有兴趣开具DAA药物，但需要开展教育、提供瞬时弹性成像检查以及明确会诊途径，以便将这种兴趣转化为更多的治疗可及性。目前注射毒品者的PBS资格需要宣传推广。
